Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis

NDT Plus

Volumn 2, Issue 4, 2009, Pages 300-302

  Jolly, Elaine C ^a   Clatworthy, Menna R ^b   Lawrence, Christopher ^a   Nathan, Paul D ^c   Farrington, Ken ^a  

^a LISTER HOSPITAL   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

acute renal impairment; CTLA 4 antibody; interstitial nephritis

Indexed keywords

ANTINUCLEAR ANTIBODY; CREATININE; DACARBAZINE; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; PREDNISOLONE; TICILIMUMAB;

ABDOMINAL CANCER; ACUTE KIDNEY FAILURE; ADULT; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE INTERSTITIAL NEPHRITIS; CASE REPORT; CD8+ T LYMPHOCYTE; DISEASE COURSE; DRUG MEGADOSE; DRUG WITHDRAWAL; HUMAN; HYDRONEPHROSIS; HYDROURETER; HYPERTENSION; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; LETHARGY; MALE; MELANOMA; NAUSEA; PELVIS CANCER; PRIORITY JOURNAL; RETROPERITONEAL CANCER; URETER OBSTRUCTION; URINALYSIS; VITILIGO; VOMITING;

EID: 77955976757     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfp048     Document Type: Article

References (14)

1. Statistical Information Team, Cancer Research UK. Available at: http://info.cancerresearchuk.org/cancerstats/
2. Hauschild A,Weichenthal M, Balda BR et al. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol 2003; 21: 2883-2888
3. van Baren N, Bonnet MC, Dreno B et al. Tumoral and immunologic response after vaccination ofmelanoma patients with an ALVAC virus encoding MAGE antigens recognised by T cells. J Clin Oncol 2005; 23: 9008-9021
4. Escudier B, Dorval T, Chaput N et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derivedexosomes: results of the first phase I clinical trial. J Transl Med 2005; 3: 10
5. MakerAV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 2005; 175: 7746-7754
6. Gogas H, Ioannovich J, Dafni U et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354: 709-718
7. Moschos SJ, Mandic M, Kirkwood JM et al. Focus on FOCIS: interleukin 2 treatment associated autoimmunity. Clin Immunol 2008; 127: 123-129
8. Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100: 8372-8377
9. Sanderson K, Scotland R, Lee P et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides andMontanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005; 23: 741-750
10. Beck KE, Blansfield JA, Tran KQ et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24: 2283-2289
11. Ribas A, Camacho LH, Lopez-Berestein G et al. Antitumor activity in Melanoma and anti-self responses in a phase I trial with the anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005; 23: 8968-8977
12. Weber J. Review: anti-CTLA-4 antibody Ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007; 12: 864-872
13. Gonzalez E, Gutierrez E, Galeano C et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int 2008; 73: 940-946
14. Kimberly RP, Lockshin MD, Sherman RL et al. High-dose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus. Am J Med 1981; 70: 817-824